

# Ponicidin suppresses HT29 cell growth via the induction of G1 cell cycle arrest and apoptosis

JIE DU, CHUNYOU CHEN, YIQUN SUN, LIN ZHENG and WANCHEN WANG

Department of General Surgery, Port Hospital of Tianjin, Tianjin 300456, P.R. China

Received October 13, 2014; Accepted June 30, 2015

DOI: 10.3892/mmr.2015.4150

**Abstract.** Ponicidin is a diterpenoid extracted from the Chinese herb *Isodon adenolomus*, which has been reported as a therapeutic cytotoxic drug that may be used to treat various types of human cancer. The present study aimed to determine the antitumor effects of ponicidin, and to investigate its underlying mechanisms in colorectal cancer. The HT29 colorectal cancer cell line was used to detect the cytotoxicity of various doses of ponicidin. Cell proliferation was measured using a Cell Counting kit-8 assay. Cell cycle and apoptosis analyses were performed using flow cytometry and fluorescent microscopy. Western blot analysis was used to measure the expression levels of apoptosis-associated proteins following treatment with ponicidin. Treatment with ponicidin significantly suppressed HT29 cell growth by inducing G1 cell cycle arrest and apoptosis. The AKT and MEK signaling pathways were also suppressed by ponicidin; however, the p38 signaling pathway was significantly activated. The expression levels of caspase 3 and Bax protein were markedly upregulated following treatment with ponicidin. These results suggest that ponicidin exerts significant antitumor effects via the induction of cell cycle arrest and apoptosis in colorectal cells. In conclusion, ponicidin acted as an inducer of apoptosis, and may be used as a therapeutic cytotoxic drug to treat human cancer, including colorectal cancer.

## Introduction

Ponicidin is a natural ent-kaurane diterpenoid, which is extracted from the traditional Chinese herb *Isodon adenolomus* (1,2). Ponicidin has been shown to possess antibacterial properties, as well as anti-inflammatory and anti-viral regulatory functions (3). Recent studies have reported that ponicidin exerts antitumor effects, and may function as a potential cytotoxic drug for the treatment of hepatocellular cancer, lung cancer, and monocytic leukemia (4-7). Zhang *et al* (4) reported that

ponicidin exerts marked anti-proliferative effects on hepatocellular cancer cells by inducing apoptosis, via the suppression of survivin and Bcl-2 expression, and the activation of Bax expression (4). Liu *et al* (7) reported the anti-proliferative effects of ponicidin on leukemia cells *in vitro*, via the down-regulation of survivin and Bcl-2 expression, thus inducing potent apoptosis. Furthermore, Zhao *et al* detected the cytotoxic effects of ponicidin in lung cancer; ponicidin was able to disrupt the mitochondrial membrane potential, and trigger the activation of caspases-3, -8 and -9 (2). These previous reports suggest that ponicidin may serve as a novel cytotoxic drug for the treatment of various types of cancer.

Colorectal cancer is the third most frequently diagnosed type of cancer, and the second leading cause of cancer-associated mortality worldwide (8). Leucovorin and fluorouracil combined with or without oxaliplatin are considered the first-line treatment in advanced colorectal cancer (9). However, after numerous rounds of treatment, the development of chemoresistance is inevitable, and the treatment of metastatic colorectal cancer remains to be improved (10). The usage of ponicidin for the treatment of colorectal cancer has not yet been investigated. In order to determine whether ponicidin has therapeutic potential in colorectal cancer, the present study aimed to determine the effects of various doses of ponicidin on cell proliferation and apoptosis *in vitro*, using the HT29 colorectal cancer cell line. In addition, the underlying molecular mechanisms of ponicidin in cancer cells were investigated.

## Materials and methods

**Reagents and cell culture.** Ponicidin was isolated from *Isodon adenolomus* (Kunming Institute of Botany, Kunming, China) as described previously (2). The HT29 human colorectal cancer cell line was obtained from the American Type Culture Collection (Manassas, VA, USA). The cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum (Sigma-Aldrich, St. Louis, MO, USA), 100 U/ml penicillin and 100  $\mu$ g/ml streptomycin (Sigma-Aldrich), in a humidified incubator containing 5% CO<sub>2</sub> at 37°C. *In vitro* experiments were conducted in triplicate at 70% cell confluence.

**Cell proliferation assay.** A total of 1x10<sup>3</sup> HT29 cells were seeded in 96-well plates and treated with various doses of ponicidin (0, 10, 20 and 50  $\mu$ g/ml), for various time-points

---

*Correspondence to:* Mr. Jie Du, Department of General Surgery, Port Hospital of Tianjin, 1482 Newport 2nd Road, Binhai New, Tianjin 300456, P.R. China  
E-mail: dzbmw025@126.com

**Key words:** ponicidin, apoptosis, colorectal cancer

(6, 12, 24 and 48 h). After incubation, the medium was removed and cell proliferation was measured using the Cell Counting kit (CCK)-8 assay kit (Dojindo Molecular Technologies, Inc., Rockville, MD, USA). CCK-8 solution (150  $\mu$ l) was added to each well and incubated for 2 h. Subsequently, the absorbance was measured at 450 nm using a microplate reader (HTX; Biotek, Beijing, China).

**Cell cycle and apoptosis analyses.** For the cell cycle analysis, flow cytometric measurements of DNA content were detected in 70% ethanol-fixed HT29 cells using propidium iodide (PI). The fixed cells (10<sup>6</sup> cells/ml) were washed with phosphate-buffered saline (PBS), treated with 200  $\mu$ g/ml RNase A (Sigma-Aldrich) for 30 min at room temperature, and stained with 50  $\mu$ g/ml PI (Sigma-Aldrich). Measurements were made using a flow cytometer (BD Influx; BD Biosciences, Franklin Lakes, NJ, USA).

For the apoptosis assay, fluorescein isothiocyanate (FITC)-conjugated Annexin-V and PI were used to detect apoptotic cells. Trypsinized cells (10<sup>6</sup> cells/ml; Sigma-Aldrich) were washed twice with PBS and resuspended in binding buffer containing Annexin-V-FITC and PI (BD Biosciences). The cells were incubated at room temperature for 15 min. The samples were analyzed using a flow cytometer (BD Biosciences).

**Hoechst 33342 staining.** Hoechst 33342 staining was used to observe the apoptotic morphology of the cells. HT29 cells (10<sup>6</sup> cells/ml), untreated or treated with ponidicin, were fixed with 4% formaldehyde in PBS for 10 min. The cells were subsequently stained with 10  $\mu$ g/ml Hoechst 33342 (Yeasen Corporation, Shanghai, China) for 1 h, and subjected to fluorescence microscopy (TE2000; Nikon, Shanghai, China).

**Western blot analysis.** Western blot analysis was performed according to a standard method (8). In brief, 10 mg protein lysates were loaded onto the SDS-PAGE gel and transferred onto the membrane. The blots were quantified by Quantity One 1-D analysis software (Bio-Rad Laboratories, Inc., Hercules, CA, USA) to measure the density of the bands. The following antibodies were used: Anti-p38 (cat. no. 8690; 1:1,000 dilution), anti-phosphorylated (p)-p38 (cat. no. 4511; 1:800 dilution), anti-AKT (cat. no. 9272S; 1:1,000 dilution), anti-p-AKT (cat. no. 4058S; 1:1,000 dilution), anti-extracellular signal-regulated kinases (ERK) (cat. no. 4376S; 1:1,000 dilution), anti-p-ERK (cat. no. 4370S; 1:1,000 dilution) and anti-GAPDH (cat. no. 5174; 1:1,500 dilution) purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA); anti-caspase 3 (cat. no. ab4051; 1:400 dilution; Abcam, Cambridge, MA, USA); anti-Bcl-2 (cat. no. sc-492; 1:100 dilution) and anti-Bax (cat. no. sc-493; 1:150 dilution) purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). Horseradish peroxidase (HRP)-anti-rabbit immunoglobulin G (IgG) (cat. no. A0208; 1:1,000 dilution) and HRP-anti-mouse IgG (cat. no. A0216; 1:1,000 dilution) were purchased from Beyotime Institute of Biotechnology (Haimen, China).

**Statistical analysis.** All experiments were performed in triplicate and the results were presented as the mean  $\pm$  standard deviation. Data were analyzed using Student's t-test, and IBM




Figure 1. Ponidicin suppressed cell proliferation. HT29 human colorectal cancer cells were treated with various doses of ponidicin (10, 20 and 50  $\mu$ g/ml) for 6, 12, 24 and 48 h. After treatment, cell proliferation was measured using the Cell Counting kit-8 assay ( $P < 0.05$ ,  $n = 3$ ). OD, optical density.

SPSS 20 software (IBM SPSS, Armonk, NY, USA) was used to conduct analyses.

## Results

**Ponidicin suppresses cell growth.** To determine the suppression of cell growth by ponidicin in colorectal cancer cells, HT29 cells were treated with various doses of ponidicin for 0, 6, 12, 24 or 48 h. As shown in Fig. 1, ponidicin exerted cell growth inhibitory effects on HT29 cells in a dose-dependent manner. The growth of the HT29 cells was markedly suppressed following 48 h treatment with 50  $\mu$ g/ml ponidicin, an  $\sim 4$  fold reduction as compared with the untreated control cells. The suppressive effects of 10 and 20  $\mu$ g/ml ponidicin were 1.5- and 2.1- fold, respectively.

**Ponidicin induces G1 cell cycle arrest.** In order to investigate the underlying mechanism of ponidicin-induced cell growth suppression, cell cycle analysis was performed on the HT29 cells treated with various doses of ponidicin. Treatment with ponidicin suppressed DNA synthesis and cell proliferation, as evidenced by a reduced percentage of S-phase cells (19.02% in the 10  $\mu$ g/ml group, 11.23% in the 20  $\mu$ g/ml group, and 7.17% in the 50  $\mu$ g/ml group, as compared with 14.05% in the control group). G1 cell cycle arrest was markedly increased following treatment with ponidicin (53.89% in the 10  $\mu$ g/ml group, 60.71% in the 20  $\mu$ g/ml group, and 66.33% in the 50  $\mu$ g/ml group, as compared with 51.02% in the control group) (Fig. 2).

**Ponidicin induces cell apoptosis.** The present study also investigated whether ponidicin-induced cell growth suppression was caused by the induction of apoptosis. The HT29 cells were stained with PI and analyzed by flow cytometry. Following treatment with ponidicin, the apoptotic rate of the HT29 cells was increased to 10.2% in the 10  $\mu$ g/ml group, 26.6% in the 20  $\mu$ g/ml group, and 70.9% in the 50  $\mu$ g/ml group, as compared with 3.9% in the untreated cells




Figure 2. Ponidicin induced cell cycle arrest. HT29 human colorectal cancer cells were treated with various doses of ponidicin (10, 20 or 50 µg/ml) for 24 h. Cell cycle analysis was performed by fluorescence-activated cell sorting (FACS) in HT29 cells. DNA was stained with propidium iodide. Relative phase group was calculated by FACS ( $P < 0.05$ ,  $n = 3$ ).




Figure 3. Ponidicin induced cell death. HT29 human colorectal cancer cells were treated with various doses of ponidicin (10, 20 and 50 µg/ml) for 24 h. The early apoptosis assay was performed by fluorescence-activated cell sorting (FACS) analysis in HT29 cells. The percentage of apoptotic cells in relation to total cell counts were plotted in the form of stacked bar diagrams. ( $P < 0.05$ ,  $n = 3$ ).




Figure 4. Ponycidin increased the number of apoptotic bodies. HT29 human colorectal cancer cells were treated with various doses of ponycidin (10, 20 and 50  $\mu\text{g/ml}$ ) for 24 h. Apoptotic bodies were visualized following Hoechst 33342 staining (magnification, x20). After treatment, apoptosis-associated morphological changes, such as chromatin condensation and apoptotic body formation were observed in HT29 cells.




Figure 5. Ponycidin regulated apoptosis-associated protein expression. (A) HT29 human colorectal cancer cells were treated with various doses of ponycidin (10, 20 and 50  $\mu\text{g/ml}$ ) for 24 h. The expression levels of cell apoptosis-associated proteins were measured by western blotting. (B) Relative protein expression levels were quantified by Quantity One software.

(Fig. 3). To further validate the apoptotic effects of ponycidin, the number of apoptotic bodies was determined in the treated cells (Fig. 4). Following treatment with ponycidin, a marked increase in the number of apoptotic bodies was detected in the HT29 cells. Treatment with 50  $\mu\text{g/ml}$  ponycidin resulted in the most apoptotic bodies, and the highest apoptotic rate in the

HT29 cells. These results were concordant with the findings regarding cell growth suppression.

*Ponycidin alters the expression levels of apoptosis-associated proteins.* In order to investigate the molecular mechanism underlying ponycidin-induced apoptosis in HT29

cells, apoptosis-associated protein expression was measured by western blot analysis. As shown in Fig. 5, the expression levels of p-p38 were markedly increased following treatment with ponicedin (4.4-fold increase in the 10  $\mu\text{g}/\text{ml}$  group, 4.4-fold increase in the 20  $\mu\text{g}/\text{ml}$  group and 8.3-fold increase in the 50  $\mu\text{g}/\text{ml}$  group), whereas total p38 protein expression levels remained unchanged. Similarly, apoptotic markers, caspase 3 and Bax were markedly upregulated in the treated cells; however, p-AKT and p-ERK were downregulated in the treated cells. These results indicate that proliferation signaling pathways were suppressed following treatment with ponicedin (Fig. 5).

## Discussion

Chinese herbal medicine is important in traditional Chinese medical treatment. Recent studies have demonstrated that Chinese herbal extracts may induce cancer cell death (11,12). Mujumdar *et al* (13) reported that the herbal extract triptolide resulted in the downregulation of GRP78 protein expression in the cells, reduced cancer cell survival, and facilitated cell death in human pancreatic cancer cells and tissue in culture. Ponicedin is a natural ent-kaurane diterpenoid compound that is extracted from the traditional Chinese herb *Isodon adenolomus* (14,15). Recent studies have reported the successful and large-scale purification of ponicedin by liquid chromatography-tandem mass spectrometry (16-19), thus indicating the practical usage of ponicedin in therapeutic applications. Xu *et al* (20) identified the DNA binding and cleavage properties of ponicedin; these properties may provide the basis for the rational construction of novel, more efficient drugs targeted to DNA, thus enabling the development of effective therapeutic agents for the target gene.

Notably, ponicedin has been shown to act as a cytotoxic drug for hepatocellular cancer, lung cancer and monocytic leukemia (1,7,12), and therefore has high potential in translational research in colorectal cancer. The present study examined the biological function of ponicedin in the HT29 colorectal cancer cell line. The results of the present study demonstrated that ponicedin was able to significantly suppress the cell growth of HT29 cells by inducing G1 cell cycle arrest and apoptosis. Treatment of HT29 cells with 50  $\mu\text{g}/\text{ml}$  ponicedin resulted in a ~4 fold suppression of cell growth, a ~15% increase in G1 cycle arrest, and a 67% increase in cell death. Further investigation demonstrated that ponicedin significantly upregulated p-p38, and suppressed the activation of the AKT and MEK signaling pathways. The p38 signaling pathway is activated by apoptotic stimuli, and induces apoptosis via its downstream targets (14,21). Subsequent activation of apoptotic marker genes, such as caspase 3 and Bax, was consistent with the activation of the p38 signaling pathway. These results suggested that ponicedin may act as an apoptotic stimulus and trigger activation of the p38 signaling pathway in colorectal cancer cells. Inducers of apoptosis have been applied in cancer therapy and activation of apoptosis is a vital process by which cytotoxic drugs destroy cancer cells (15,22). In conclusion, the results of previous studies and of the present study suggest that ponicedin may be used as a therapeutic cytotoxic drug for the treatment of human cancers, including colorectal cancer.

## References

- Zhang JX, Han QB, Zhao AH and Sun HD: Diterpenoids from *Isodon japonica*. *Fitoterapia* 74: 435-438, 2003.
- Zhao W, Pu JX, Du X, Su J, Li XN, Yang JH, Xue YB, Li Y, Xiao WL and Sun HD: Structure and cytotoxicity of diterpenoids from *Isodon adenolomus*. *J Nat Prod* 74: 1213-1220, 2011.
- Osawa K, Yasuda H, Maruyama T, Morita H, Takeya K and Itokawa H: Antibacterial trichorabdol diterpenes from *Rabdosia trichocarpa*. *Phytochemistry* 36: 1287-1291, 1994.
- Zhang JF, Liu PQ, Chen GH, Lu MQ, Cai CJ, Yang Y and Li H: Ponicedin inhibits cell growth on hepatocellular carcinoma cells by induction of apoptosis. *Dig Liver Dis* 39: 160-166, 2007.
- Liu JJ, Huang RW, Lin DJ, Peng J, Zhang M, Pan X, Hou M, Wu XY, Lin Q and Chen F: Ponicedin, an ent-kaurane diterpenoid derived from a constituent of the herbal supplement PC-SPES, *Rabdosia rubescens*, induces apoptosis by activation of caspase-3 and mitochondrial events in lung cancer cells in vitro. *Cancer Invest* 24: 136-148, 2006.
- Bai N, He K, Zhou Z, Tsai ML, Zhang L, Quan Z, Shao X, Pan MH and Ho CT: Ent-kaurane diterpenoids from *Rabdosia rubescens* and their cytotoxic effects on human cancer cell lines. *Planta Med* 76: 140-145, 2010.
- Liu JJ, Zhang Y, Guang WB, Yang HZ, Lin DJ and Xiao RZ: Ponicedin inhibits monocytic leukemia cell growth by induction of apoptosis. *Int J Mol Sci* 9: 2265-2277, 2008.
- Zhou Y, Wan G, Spizzo R, Ivan C, Mathur R, Hu X, Ye X, Lu J, Fan F, Xia L, *et al*: miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase. *Mol Oncol* 8: 83-92, 2014.
- de Gramont A, Figuer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, *et al*: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. *J Clin Oncol* 18: 2938-2947, 2000.
- Dallas NA, Xia L, Fan F, Gray MJ, Gaur P, van Buren G II, Samuel S, Kim MP, Lim SJ and Ellis LM: Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. *Cancer Res* 69: 1951-1957, 2009.
- Ergil KV, Kramer EJ and Ng AT: Chinese herbal medicines. *West J Med* 176: 275-279, 2002.
- Au AM, Ko R, Boo FO, Hsu R, Perez G and Yang Z: Screening methods for drugs and heavy metals in Chinese patent medicines. *Bull Environ Contam Toxicol* 65: 112-119, 2000.
- Mujumdar N, Banerjee S, Chen Z, Sangwan V, Chugh R, Dudeja V, Yamamoto M, Vickers SM and Saluja AK: Triptolide activates unfolded protein response leading to chronic ER stress in pancreatic cancer cells. *Am J Physiol Gastrointest Liver Physiol* 306: G1011-G1020, 2014.
- Kostenko S, Dumitriu G, Lægred KJ and Moens U: Physiological roles of mitogen-activated-protein-kinase-activated p38-regulated/activated protein kinase. *World J Biol Chem* 2: 73-89, 2011.
- Tsuruo T, Naito M, Tomida A, Fujita N, Mashima T, Sakamoto H and Haga N: Molecular targeting therapy of cancer: Drug resistance, apoptosis and survival signal. *Cancer Sci* 94: 15-21, 2003.
- Li X, Chu Y, Du B, Wang L and Yu T: LC-MS-MS for the determination of ponicedin in dog plasma. *J Chromatogr Sci* 52: 211-217, 2014.
- Ma B, Wang Y, Zhang Q, Liu Y, Li J, Xu Q and Ying H: Simultaneous determination of oridonin, ponicedin and rosmarinic acid from Herba *Isodi Rubescens* extract by LC-MS-MS in rat plasma. *J Chromatogr Sci* 51: 910-918, 2013.
- Li X, Hou W, Song J, Liu H, Song S, Zhang L and Shi Y: A simple and sensitive HPLC-UV method for the determination of ponicedin in rat plasma and its application in a pharmacokinetic study. *Biomed Chromatogr* 25: 362-366, 2011.
- Du Y, Liu P, Shi X, Jin Y, Wang Q, Zhang X, Sheng X and Zhang L: A novel analysis method for diterpenoids in rat plasma by liquid chromatography-electrospray ionization mass spectrometry. *Anal Biochem* 407: 111-119, 2010.
- Xu X, Ke Y, Zhang Q, Qi X and Liu H: DNA binding and cleavage properties of ponicedin. *Tumori* 95: 348-351, 2009.
- Cuadrado A and Nebreda AR: Mechanisms and functions of p38 MAPK signalling. *Biochem J* 429: 403-417, 2010.
- Perego P, Cossa G, Zuco V and Zunino F: Modulation of cell sensitivity to antitumor agents by targeting survival pathways. *Biochem Pharmacol* 80: 1459-1465, 2010.